Abstract:4054 Background: In this study, we developed a stacked ensemble model that leverages cell-free DNA (cfDNA) fragmentation for the early detection of esophageal squamous cell carcinoma (ESCC). The model combined four fragmentomics features obtained from whole genome sequencing (WGS) and employed four machine learning algorithms. We evaluated the model’s generalizability in an independent validation cohort and an external cohort collected at different center. Additionally, the model’s robustness and repeatability were assessed across low coverage and repeated measured samples. The results underscore the promising potential of our model as an effective strategy for early diagnosis and management of ESCC in clinical settings. Methods: 256 healthy individuals and 243 patients diagnosed with esophageal cancer were enrolled in this study, including 47 healthy participants and 44 patients in the external cohort. Plasma samples from all participants were profiled by whole-genome sequencing (WGS). Fragmentomic features encompassed copy number variation (CNV), fragmentation size coverage (FSC), fragmentation size distribution (FSD), and nucleosome positioning (NP) were incorporated alongside machine learning models to develop an optimized classification model. The model generated a cancer score ranging from 0 to 1 for each cancer and noncancer sample, with a score closer to 1 indicating a higher probability of cancer. The performance of this model was assessed using an independent validation cohort and an external cohort, and model’s robustness and reproducibility were examined. Results: A stacked ensemble model was developed by integrating four cfDNA features and four machine learning algorithms. This integrated model exhibiting remarkable sensitivity of 91.8% (89/97) and specificity of 98.1% (102/104), and AUC of 0.986 in the independent validation cohorts using the cut-off of 0.69 selected at a specificity level of 98% (105) in the training cohort. The external cohort demonstrated a sensitivity of 86.4% (38/44) and a specificity of 95.7% (45/47) with the same cut-off. The model's performance remained consistent even at low sequencing coverage depths of 0.5× (AUC 0.978), providing valuable insights into the resilience and stability of our methodology and ascertained its practical applicability in scenarios with limited sequencing resources or constraints. Furthermore, our model demonstrated sensitivity in identifying early pathological features, with a sensitivity of 94.1% (16/17) for stage I and 91.4% (53/58) for tumors smaller than 3 cm. Conclusions: A stacked ensemble model was implemented in this study, utilizing cfDNA fragmentomics features with exceptional sensitivity for early detection of esophageal squamous cell carcinoma. The anticipated impact of this model is the enhancement of early detection strategies for esophageal cancer in clinical setting.

Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

[Development and Validation of Predictive Models for Esophageal Squamous Cell Carcinoma and Its Precancerous Lesions Using Terminal Motif Analysis in Circulating Cell-Free DNA].

Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection

Multi-Dimensional Cell-free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer

Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions

Evaluation and integration of cell-free DNA signatures for detection of lung cancer

585P Fragmentomics Early Detection Assay Leading to Potential Clinical Benefits in Colorectal Cancer

Plasma Cell-Free DNA 5-Hydroxymethylcytosine and Whole-Genome Sequencing Signatures for Early Detection of Esophageal Cancer

Non-invasive detection of esophageal carcinoma by integrative analysis of low-pass whole methylome sequencing of plasma cell-free DNA.

Figure S5 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer

Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer

Discovery and validation of methylation signatures in circulating cell-free DNA for early detection of esophageal cancer: A case-control study.

Early detection of colorectal adenocarcinoma by decoding epigenetic and DNA fragmentation fingerprints of plasma cell-free DNA.

Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Early cancer detection using low-coverage whole-genome sequencing of cell-free DNA fragments.

Early Detection and Stratification of Colorectal Cancer Using Plasma Cell-Free DNA Fragmentomic Profiling

Early Diagnostic Markers for Esophageal Squamous Cell Carcinoma: CNA Gene Identification and cfDNA Detection

Early Diagnostic Markers for Esophageal Squamous Cell Carcinoma: Copy Number Alteration Gene Identification and Cfdna Detection.

Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma

GaEsSeer: Early detection of gastric and esophageal cancer by integrating methylation and fragmentomics signatures in cfDNA.